Hikari Power’s Corcept Therapeutics CORT Stock Holding History

Hikari Power’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-16,790	Closed	-$200K	–	64
2020 Q1	$200K	Hold	16,790	–	–	0.03%	69
2019 Q4	$203K	Hold	16,790	–	–	0.02%	102
2019 Q3	$237K	Hold	16,790	–	–	0.03%	89
2019 Q2	$187K	Buy	+16,790	New	+$187K	0.02%	105
2018 Q3	–	Sell	-30,000	Closed	-$472K	–	130
2018 Q2	$472K	Buy	+30,000	New	+$522K	0.05%	79

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Hikari Power's CORT Position: Q2 2020 in Review

Hikari Power sold out of Corcept Therapeutics (CORT) in Q2 2020, closing a stake of 16,790 shares — an estimated $200K sold.

Hikari Power first reported a position in CORT in Q2 2018 and held it in 5 quarters. The position peaked at $472K in Q2 2018. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2020.

Hikari Power reported no remaining Corcept Therapeutics position as of Q2 2020 after selling out during the quarter.
Hikari Power sold 16,790 Corcept Therapeutics shares in Q2 2020, an estimated $200K.
Hikari Power first reported a position in Corcept Therapeutics in Q2 2018 and held it in 5 quarters.
Hikari Power's Corcept Therapeutics position peaked at $472K in Q2 2018.
224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2020.

Based on Hikari Power's 13F filing for Q2 2020, filed 13 Aug 2020.